Matthew Young

Mr. Young is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina for $8 billion in 2021. Prior to joining GRAIL, Mr. Young served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals (JAZZ), an LVP1 portfolio company. Prior to joining Jazz, Mr. Young worked in investment banking for approximately 20 years. From February 2009 to April 2013, he served as a Managing Director in global healthcare of Barclays Capital, where he served as co-head of the life sciences group. From 2007 to 2008, Mr. Young served as a Managing Director of Citigroup, and from 2003 to 2007, as a Managing Director of Lehman Brothers. Mr. Young holds an MBA and a BS in Economics from the Wharton School of the University of Pennsylvania.